Researchers Submit Patent Application, "Anti-Ptcra Antibody-Drug Conjugates And Uses Thereof", for Approval (USPTO 20240101672).
In: Hematology Week, 2024-04-18, S. 4212-4212
serialPeriodical
Zugriff:
A patent application has been submitted for "Anti-Ptcra Antibody-Drug Conjugates And Uses Thereof" by inventors Frank Kuhnert, Thomas Nittoli, and Michael Van Meter. The application describes the development of antibody-drug conjugates (ADCs) that target tumor cells expressing the Pre T-Cell Antigen Receptor Alpha (PTCRA) protein. The ADCs are conjugated to a therapeutic moiety and have the potential to be used in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and other diseases that involve PTCRA. This research aims to address the lack of targeted therapies for T-ALL and improve disease outcomes. [Extracted from the article]
Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Anti-Ptcra Antibody-Drug Conjugates And Uses Thereof", for Approval (USPTO 20240101672).
|
---|---|
Zeitschrift: | Hematology Week, 2024-04-18, S. 4212-4212 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-673X (print) |
Schlagwort: |
|
Sonstiges: |
|